This article is more than 5 years old. Information may no longer be current.

FDA approves Kanjinti, biosimilar to Herceptin

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA approved trastuzumab-anns for the treatment of HER2-overexpressing breast cancer, as well as metastatic gastric or gastroesophageal junction adenocarcinoma.

Trastuzumab-anns (Kanjinti, Amgen) — a HER2 receptor antagonist — is a biosimilar to trastuzumab (Herceptin, Genentech).

Trastuzumab-anns is the fifth biosimilar to trastuzumab to receive FDA approval.

Biosimilars are biological products that have been shown to be highly similar to an already-approved biological product. The preapproved agents are called reference products.

Biosimilars must have no clinically meaningful differences from their reference products with regard to effectiveness or safety. Only small differences in clinically inactive components are allowable with biosimilar products.